Supplementary Tables S1-S31 from PRECISE: A Prognostic Thyrocyte-Derived Gene Signature for Papillary Thyroid Carcinoma

Le résumé fourni par la source

Supplemental Table 1. Single-nucleus RNA sequencing sample information Supplemental Table 2. Canonical gene markers for cell type annotation Supplemental Table 3. PRECISE genes and their direct interactors Supplemental Table 4. List of all the genes from bulk RNA sequencing used for ranking Supplemental Table 5. Genes used calculate the MAP score Supplemental Table 6. PRECISE genes Supplemental Table 7. Gene enrichment overlap analysis for PRECISE gene set Supplemental Table 8. Gene enrichment overlap analysis for PRECISE genes and direct interactors Supplemental Table 9. Gene set enrichment analysis of PRECISE and network-associated genes Supplemental Table 10. Censoring rates across the three cohorts for progression-free and disease-specific survival Supplemental Table 11. Spearman's correlation analyses between PRECISE score and tumor purity Supplemental Table 12. Multivariate Cox proportional hazards with all covariates for progression-free survival in the MDACC, VUMC, and TCGA cohorts. Supplemental Table 13. Univariate and multivariate Cox proportional hazards models using Firth’s penalized likelihood for progression-free survival in the MDACC, VUMC, and TCGA cohorts Supplemental Table 14. Jackknife pseudo-value regression analysis of 2- and 5-year restricted mean survival time for progression-free survival Supplemental Table 15. Univariate and multivariate Coxproportional hazards models for disease-specific survival in the MDACC, VUMC, and TCGA cohorts. Supplemental Table 16. Multivariate Cox proportional hazards models for disease-specific survival in the MDACC cohort. Supplemental Table 17. Univariate and multivariate Cox proportional hazards models using Firth's penalized likelihood for disease-specific survival in the MDACC, VUMC, and TCGA cohorts Supplemental Table 18. Jackknife pseudo-value regression analysis of 2- and 5-year restricted mean survival time for disease-free survival Supplemental Table 19. Performance of predictive models for progression-free survival in the MDACC, VUMC, and TCGA cohorts Supplemental Table 20. Predictive models for progression-free survival in the MDACC, VUMC, and TCGA cohorts Supplemental Table 21. Prediction models for disease-specific survival in the MDACC cohort Supplemental Table 22. Univariate Cox proportional hazards models for progression-free survival in T stage-stratified subgroups Supplemental Table 23. Univariate Cox proportional hazards models for progression-free survival in BRAF-stratified subgroups Supplemental Table 24. Univariate Cox proportional hazards models for progression-free survival in BRAF-stratified subgroups with additional BRAF wild-type stratification Supplemental Table 25. Univariate Cox proportional hazards analysis stratified by median ESTIMATE score and fibrosis score Supplemental Table 26. Multivariate Cox-proportional hazards models with TERT promotor mutation status for progression-free survival and disease-specific survival in the MDACC cohort Supplemental Table 27. Spearman correlation of PRECISE with TDS and MAP scores Supplemental Table 28. Univariate and multivariate Cox proportional hazards models with Firth's penalized likelihood for PRECISE score and TDS in progression-free survival Supplemental Table 29. Univariate and multivariate Cox proportional hazards models with Firth's penalized likelihood for PRECISE score and TDS in disease-specific survival Supplemental Table 30. Multivariate Cox proportional hazards models with Firth's penalized likelihood for PRECISE score and MAP score Supplemental Table 31. Clinicopathologic characteristics of the fine needle aspiration cohort (n = 33).

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.